Literature DB >> 18537019

Infliximab treatment in refractory Kawasaki syndrome.

Meenakshi Girish1, Girish Subramaniam.   

Abstract

Kawasaki syndrome is one of the commonest vasculitides in pediatric age group with devastating consequences if not treated early. Intravenous Gammaglobulin leads to rapid amelioration of clinical symptoms and significantly decreases the risk of development of coronary artery aneurysms. Occasionally, Kawasaki disease may be resistant to I/V IgG. We present our experience with one such patient who ultimately respondend to infliximab therapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18537019     DOI： 10.1007/s12098-008-0084-8

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


  10 in total

1.  Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease.

Authors:  Jane C Burns; Chisato Shimizu; Enrique Gonzalez; Hemant Kulkarni; Sukeshi Patel; Hiroko Shike; Robert S Sundel; Jane W Newburger; Sunil K Ahuja
Journal:  J Infect Dis       Date:  2005-06-08       Impact factor: 5.226

2.  Nationwide survey of Kawasaki disease and acute rheumatic fever.

Authors:  K A Taubert; A H Rowley; S T Shulman
Journal:  J Pediatr       Date:  1991-08       Impact factor: 4.406

3.  Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease.

Authors:  M Wong; E D Silverman; E N Fish
Journal:  J Rheumatol       Date:  1997-06       Impact factor: 4.666

4.  Kawasaki disease: are we missing the diagnosis?

Authors:  M R Sridhar; Himanshu Goel; Deepa Anirudh; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2005-10       Impact factor: 1.967

5.  Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

6.  Infliximab treatment for refractory Kawasaki syndrome.

Authors:  Jane C Burns; Wilbert H Mason; Sarmistha B Hauger; Hillel Janai; John F Bastian; Julie D Wohrley; Ian Balfour; Cynthia A Shen; Edward D Michel; Stanford T Shulman; Marian E Melish
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

7.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

8.  Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan.

Authors:  H Yanagawa; M Yashiro; Y Nakamura; T Kawasaki; H Kato
Journal:  Arch Pediatr Adolesc Med       Date:  1995-07

9.  Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease.

Authors:  D Y Leung; R S Cotran; E Kurt-Jones; J C Burns; J W Newburger; J S Pober
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

Review 10.  Current perspectives on Kawasaki disease.

Authors:  Monesha Gupta-Malhotra; P Syamasundar Rao
Journal:  Indian J Pediatr       Date:  2005-07       Impact factor: 1.967
  10 in total
  5 in total

1.  Refractory Kawasaki disease: infliximab or methotrexate therapy?

Authors:  Jae Il Shin; Jae Seung Lee; Jae Young Choi; Dong Soo Kim; Meenakshi Girish
Journal:  Indian J Pediatr       Date:  2009-11       Impact factor: 1.967

Review 2.  Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks.

Authors:  Alessandra Marchesi; Isabella Tarissi de Jacobis; Donato Rigante; Alessandro Rimini; Walter Malorni; Giovanni Corsello; Grazia Bossi; Sabrina Buonuomo; Fabio Cardinale; Elisabetta Cortis; Fabrizio De Benedetti; Andrea De Zorzi; Marzia Duse; Domenico Del Principe; Rosa Maria Dellepiane; Livio D'Isanto; Maya El Hachem; Susanna Esposito; Fernanda Falcini; Ugo Giordano; Maria Cristina Maggio; Savina Mannarino; Gianluigi Marseglia; Silvana Martino; Giulia Marucci; Rossella Massaro; Christian Pescosolido; Donatella Pietraforte; Maria Cristina Pietrogrande; Patrizia Salice; Aurelio Secinaro; Elisabetta Straface; Alberto Villani
Journal:  Ital J Pediatr       Date:  2018-08-30       Impact factor: 2.638

3.  Childhood cutaneous vasculitis: a comprehensive appraisal.

Authors:  Aparna Palit; Arun C Inamadar
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

4.  Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report.

Authors:  Robert J Brogan; Despina Eleftheriou; James Gnanapragasam; Nigel J Klein; Paul A Brogan
Journal:  Pediatr Rheumatol Online J       Date:  2009-01-21       Impact factor: 3.054

5.  Cordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via activating amp-activated protein kinase (AMPK) signaling.

Authors:  Jian-Li Zhang; Ying Xu; Jie Shen
Journal:  Int J Mol Sci       Date:  2014-07-08       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.